Swiss pharmaceuticals powerhouse Roche says it plans to invest $50 billion in the United States over the next five years and ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on April 24 and set a price target of ...

The U.S. pays the most for drugs in the world, often nearly three times that of other developed nations. "European price ...

Sanofi, Novartis CEOs urge EU list price closer to US net levels Comes after EU pharma warn tariffs could expedite shift to US US pays nearly three times more than developed nations for drugs ...

Swiss drugmaker Roche (RHHBY) announced its decision to invest $50 billion in the U.S. towards pharmaceuticals and ...

Roche on Tuesday said it would invest $50 billion in the United States over the next five years, a day before Swiss Finance ...

Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, becoming the latest pharmaceutical company to shift operations to the ...

ZURICH (Reuters) - Roche on Tuesday said it will invest $50 billion in the United States over the next five years, in one of ...

Now, as the Trump administration reportedly weighs resurrecting a previously failed international reference program for drug prices in the States, CEOs from Novartis and Sanofi are airing their ...